Back to Research

Organization profile

Novigenix

Novigenix is a Swiss precision medicine company that specializes in AI-powered liquid biopsy solutions to decode the human immune response for early cancer detection and therapy optimization. The company’s LITOSeek platform integrates immuno-transcriptomic profiling with genomic data to provide biopharma partners and oncologists with predictive insights into patient treatment response and toxicity risk.

Epalinges, SwitzerlandFounded 2012

Overview

1. Executive Summary (Confidence: High)

Novigenix is a leader in "Immune Intelligence," recently completing a strategic spin-out in 2026 to separate its colorectal cancer (CRC) screening business from its biopharma-focused AI platform. The new entity, Novigenix AI, exclusively commercializes the LITOSeek platform, which analyzes whole-blood mRNA to predict therapy response and adverse event risks for checkpoint inhibitors and other immunotherapies. Backed by an ISO 13485-certified analytics platform and €1.8 million in EU funding from the BRECISE consortium, Novigenix is industrializing its AI solutions for prostate and bladder cancers. By shifting oncology from reactive to predictive, Novigenix provides a longitudinal view of patient immune status that traditional tissue biopsies cannot offer.

Unlock the full profileGet the complete company dossier

This public view only shows an extract. Open the full profile to access the complete company intelligence record, including the full write-up and structured research details.

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.